닥터로빈

비상장계속사업자

DRROBBIN

송경석,김미혜

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

닥터로빈

Business Reg. No. 2118773725 · CEO 송경석,김미혜

I.Investment Overview

Target닥터로빈 (2118773725)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명닥터로빈
영문명DRROBBIN
대표자송경석,김미혜
사업자등록번호2118773725
법인등록번호1101113343037
설립일2005.11.16

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW144.52021165.72022165.32023144.32024125.82025
영업이익100M KRW2.220212.42022-6.42023-21.12024-21.32025
순이익100M KRW3.620213.42022-5.42023-20.82024-20.72025
Item20252024202320222021
자산총계77.3억원71.5억원81.4억원80.8억원74.2억원
부채총계21.8억원34억원23.2억원17.1억원13.9억원
자본총계55.5억원37.4억원58.2억원63.6억원60.3억원
매출액125.8억원144.3억원165.3억원165.7억원144.5억원
영업이익-21.3억원-21.1억원-6.4억원2.4억원2.2억원
순이익-20.7억원-20.8억원-5.4억원3.4억원3.6억원

VI.Financial Ratios

FY2025 basis

-16.9%

영업이익률

-16.42%

순이익률

-26.74%

ROA

-37.24%

ROE

39.3%

부채비율

71.79%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

닥터로빈 투심보고서 | Alpha Lenz